Do analysts rate SCNX or OPTH?

Scienture presently has a consensus target price of $37.50, indicating a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher probable upside, research analysts clearly believe Scienture is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SCNX or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Optimi Health N/A N/A N/A

Does the media favor SCNX or OPTH?

In the previous week, Scienture had 6 more articles in the media than Optimi Health. MarketBeat recorded 9 mentions for Scienture and 3 mentions for Optimi Health. Scienture's average media sentiment score of 0.50 beat Optimi Health's score of 0.00 indicating that Scienture is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scienture 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Optimi Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PLRZ or SCNX?

Scienture has a consensus price target of $37.50, indicating a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, PLRZ or SCNX?

Polyrizon has higher earnings, but lower revenue than Scienture. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Scienture $430K 14.34 -$41.51M -$2.10 N/A

Is PLRZ or SCNX more profitable?

Polyrizon's return on equity of 0.00% beat Scienture's return on equity. Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Scienture N/A -53.51% -42.47%

Does the media prefer PLRZ or SCNX?

In the previous week, Scienture had 3 more articles in the media than Polyrizon. MarketBeat recorded 9 mentions for Scienture and 6 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.58 beat Scienture's score of 0.50 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scienture 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SCNX or TXMD?

Scienture currently has a consensus price target of $37.50, suggesting a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher possible upside, research analysts clearly believe Scienture is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SCNX or TXMD?

In the previous week, Scienture had 6 more articles in the media than TherapeuticsMD. MarketBeat recorded 9 mentions for Scienture and 3 mentions for TherapeuticsMD. Scienture's average media sentiment score of 0.50 beat TherapeuticsMD's score of 0.00 indicating that Scienture is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scienture 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AYTU or SCNX?

In the previous week, Aytu BioPharma had 7 more articles in the media than Scienture. MarketBeat recorded 16 mentions for Aytu BioPharma and 9 mentions for Scienture. Scienture's average media sentiment score of 0.50 beat Aytu BioPharma's score of 0.16 indicating that Scienture is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aytu BioPharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Scienture 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SCNX or COCP?

Scienture currently has a consensus price target of $37.50, suggesting a potential upside of 897.34%. Given Scienture's higher probable upside, equities research analysts plainly believe Scienture is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scienture 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SCNX or COCP more profitable?

Scienture's return on equity of -53.51% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scienture N/A -53.51% -42.47% Cocrystal Pharma N/A -207.47% -123.33%

Scienture (SCNX) Competitors

$3.76 -0.10 (-2.59%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.72 -0.04 (-1.06%)

As of 10/9/2026 07:47 PM Eastern

Compare

SCNX vs. OPTH, PLRZ, TXMD, AYTU, and COCP

Should you buy Scienture stock or one of its competitors? Scienture's main competitors and comparable companies include Optimi Health (OPTH), Polyrizon (PLRZ), TherapeuticsMD (TXMD), Aytu BioPharma (AYTU), and Cocrystal Pharma (COCP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Scienture compare to Optimi Health?

Scienture (NASDAQ:SCNX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Optimi Health's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Optimi Health	N/A	N/A	N/A

5.7% of Scienture shares are owned by institutional investors. 19.5% of Scienture shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Optimi Health has lower revenue, but higher earnings than Scienture. Optimi Health is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	14.34	-$41.51M	-$2.10	N/A
Optimi Health	$310K	74.31	-$1.12M	-$0.76	N/A

In the previous week, Scienture had 6 more articles in the media than Optimi Health. MarketBeat recorded 9 mentions for Scienture and 3 mentions for Optimi Health. Scienture's average media sentiment score of 0.50 beat Optimi Health's score of 0.00 indicating that Scienture is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scienture	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Optimi Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scienture presently has a consensus target price of $37.50, indicating a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher probable upside, research analysts clearly believe Scienture is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Scienture beats Optimi Health on 9 of the 14 factors compared between the two stocks.

How does Scienture compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Polyrizon has higher earnings, but lower revenue than Scienture.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Scienture	$430K	14.34	-$41.51M	-$2.10	N/A

Polyrizon's return on equity of 0.00% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Scienture	N/A	-53.51%	-42.47%

Polyrizon has a beta of -1.2, meaning that its stock price is 220% less volatile than the broader market. Comparatively, Scienture has a beta of 3.34, meaning that its stock price is 234% more volatile than the broader market.

In the previous week, Scienture had 3 more articles in the media than Polyrizon. MarketBeat recorded 9 mentions for Scienture and 6 mentions for Polyrizon. Polyrizon's average media sentiment score of 0.58 beat Scienture's score of 0.50 indicating that Polyrizon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scienture	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scienture has a consensus price target of $37.50, indicating a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher possible upside, analysts clearly believe Scienture is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.7% of Scienture shares are held by institutional investors. 19.5% of Scienture shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Scienture beats Polyrizon on 8 of the 12 factors compared between the two stocks.

How does Scienture compare to TherapeuticsMD?

Scienture (NASDAQ:SCNX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, Scienture had 6 more articles in the media than TherapeuticsMD. MarketBeat recorded 9 mentions for Scienture and 3 mentions for TherapeuticsMD. Scienture's average media sentiment score of 0.50 beat TherapeuticsMD's score of 0.00 indicating that Scienture is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scienture	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scienture has a beta of 3.34, indicating that its share price is 234% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

5.7% of Scienture shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 19.5% of Scienture shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Scienture currently has a consensus price target of $37.50, suggesting a potential upside of 897.34%. Given Scienture's stronger consensus rating and higher possible upside, research analysts clearly believe Scienture is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scienture has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Scienture's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

TherapeuticsMD has higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	14.34	-$41.51M	-$2.10	N/A
TherapeuticsMD	$3.02M	7.89	-$570K	$0.02	103.00

Summary

Scienture beats TherapeuticsMD on 9 of the 16 factors compared between the two stocks.

How does Scienture compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Scienture has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Scienture's return on equity of -53.51% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-56.54%	-13.14%
Scienture	N/A	-53.51%	-42.47%

Aytu BioPharma currently has a consensus price target of $14.50, indicating a potential upside of 614.29%. Scienture has a consensus price target of $37.50, indicating a potential upside of 897.34%. Given Scienture's higher probable upside, analysts clearly believe Scienture is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scienture	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aytu BioPharma had 7 more articles in the media than Scienture. MarketBeat recorded 16 mentions for Aytu BioPharma and 9 mentions for Scienture. Scienture's average media sentiment score of 0.50 beat Aytu BioPharma's score of 0.16 indicating that Scienture is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scienture	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aytu BioPharma has higher revenue and earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$57.57M	0.38	-$14.25M	-$1.66	N/A
Scienture	$430K	14.34	-$41.51M	-$2.10	N/A

Aytu BioPharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Scienture has a beta of 3.34, suggesting that its stock price is 234% more volatile than the broader market.

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 19.5% of Scienture shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Scienture beats Aytu BioPharma on 8 of the 15 factors compared between the two stocks.

How does Scienture compare to Cocrystal Pharma?

Scienture (NASDAQ:SCNX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Scienture had 7 more articles in the media than Cocrystal Pharma. MarketBeat recorded 9 mentions for Scienture and 2 mentions for Cocrystal Pharma. Scienture's average media sentiment score of 0.50 beat Cocrystal Pharma's score of 0.00 indicating that Scienture is being referred to more favorably in the media.

Company	Overall Sentiment
Scienture	Neutral
Cocrystal Pharma	Neutral

Cocrystal Pharma has lower revenue, but higher earnings than Scienture. Scienture is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430K	14.34	-$41.51M	-$2.10	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Scienture has a beta of 3.34, indicating that its share price is 234% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

5.7% of Scienture shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 19.5% of Scienture shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scienture's return on equity of -53.51% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Scienture currently has a consensus price target of $37.50, suggesting a potential upside of 897.34%. Given Scienture's higher probable upside, equities research analysts plainly believe Scienture is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Scienture beats Cocrystal Pharma on 8 of the 12 factors compared between the two stocks.

Get Scienture News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNX vs. The Competition

Export

Metric	Scienture	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.34M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.07	797.58	274.15	26.16
Price / Sales	14.34	939.82	635.98	112.53
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.09	10.71	11.21	6.34
Net Income	-$41.51M	$2.84B	$3.50B	$381.90M
7 Day Performance	-5.29%	-0.93%	-0.90%	-1.41%
1 Month Performance	-57.93%	-4.91%	-4.44%	-3.48%
1 Year Performance	-78.55%	-4.13%	6.96%	1.16%

Scienture Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNX Scienture	2.6688 of 5 stars	$3.76 -2.6%	$37.50 +897.3%	-80.3%	$6.34M	$430K	N/A	9
OPTH Optimi Health	0.237 of 5 stars	$4.04 -2.2%	N/A	N/A	$23.65M	$310K	N/A	9
PLRZ Polyrizon	1.3362 of 5 stars	$9.15 -5.4%	N/A	+19.9%	$23.48M	N/A	N/A	1	Analyst Downgrade Gap Down
TXMD TherapeuticsMD	1.0101 of 5 stars	$2.00 -1.0%	N/A	+94.3%	$23.38M	$3.02M	100.00	420	News Coverage Positive News Gap Up High Trading Volume
AYTU Aytu BioPharma	2.9225 of 5 stars	$2.05 flat	$14.50 +607.3%	-19.1%	$22.28M	$57.57M	N/A	83	Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scienture (SCNX) Competitors

SCNX vs. OPTH, PLRZ, TXMD, AYTU, and COCP

How does Scienture compare to Optimi Health?

Summary

How does Scienture compare to Polyrizon?

Summary

How does Scienture compare to TherapeuticsMD?

Summary

How does Scienture compare to Aytu BioPharma?

Summary

How does Scienture compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX vs. The Competition

Scienture Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scienture (SCNX) Competitors

SCNX vs. OPTH, PLRZ, TXMD, AYTU, and COCP

How does Scienture compare to Optimi Health?

Is SCNX or OPTH more profitable?

Do insiders & institutionals believe in SCNX or OPTH?

Which has preferable earnings & valuation, SCNX or OPTH?

Does the media favor SCNX or OPTH?

Do analysts rate SCNX or OPTH?

Summary

How does Scienture compare to Polyrizon?

Which has higher earnings and valuation, PLRZ or SCNX?

Is PLRZ or SCNX more profitable?

Which has more volatility & risk, PLRZ or SCNX?

Does the media prefer PLRZ or SCNX?

Do analysts rate PLRZ or SCNX?

Do insiders and institutionals have more ownership in PLRZ or SCNX?

Summary

How does Scienture compare to TherapeuticsMD?

Does the media prefer SCNX or TXMD?

Which has more volatility and risk, SCNX or TXMD?

Do insiders & institutionals hold more shares of SCNX or TXMD?

Do analysts rate SCNX or TXMD?

Is SCNX or TXMD more profitable?

Which has stronger earnings and valuation, SCNX or TXMD?

Summary

How does Scienture compare to Aytu BioPharma?

Is AYTU or SCNX more profitable?

Do analysts recommend AYTU or SCNX?

Does the media refer more to AYTU or SCNX?

Which has preferable earnings & valuation, AYTU or SCNX?

Which has more risk & volatility, AYTU or SCNX?

Do institutionals and insiders believe in AYTU or SCNX?

Summary

How does Scienture compare to Cocrystal Pharma?

Does the media favor SCNX or COCP?

Which has stronger earnings and valuation, SCNX or COCP?

Which has more volatility & risk, SCNX or COCP?

Do insiders and institutionals hold more shares of SCNX or COCP?

Is SCNX or COCP more profitable?

Do analysts recommend SCNX or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX vs. The Competition

Scienture Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools